Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial

Marie Scully, Spero Cataland, Paul Coppo, Paul Knoebl, Paul Brinkkoetter, Javier de la Rubia, Marielle Klein Hesselink, Josefin-Beate Holz, Flora Peyvandi

Blood (2025) 146 (Supplement 1): 849.

https://doi.org/10.1182/blood-2025-849

Published: 2025

Journal Articles

A diagnostic hematology clinic pilot program: Increasing access and optimizing resources

Kathryn Knisely, Marina Beltrami Moreira, Roberta Azbell, Lindsay Hunter, Christine Harsh, Tina Sowers, Raquel Reinbolt, Samantha Knight, Rupa Ghosh-Berkebile, Victoria Krogg, Spero Cataland, Regina Crawford, Sherraine Della-Moretta, Nicolas Gallastegui-Crestani, Jennifer Vaughn

Blood (2025) 146 (Supplement 1): 597.

https://doi.org/10.1182/blood-2025-597

Published: 2025

Journal Articles

Expert consensus on the clinical management of congenital thrombotic thrombocytopenic purpura in Asia-Pacific: A modified Delphi panel

Hyoung Jin Kang, Fernanda Orsi, Spero Cataland, Jerzy Windyga

Blood (2025) 146 (Supplement 1): 2608.

https://doi.org/10.1182/blood-2025-2608

Published: 2025

Journal Articles

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

Blood (2025) 146 (Supplement 1): 848.

https://doi.org/10.1182/blood-2025-848

Published: 2025

Journal Articles

Clinical management of congenital thrombotic thrombocytopenic purpura in Latin America: Expert consensus from a modified Delphi panel

Fernanda Orsi, Hyoung Jin Kang, Jerzy Windyga, Spero Cataland

Blood (2025) 146 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2025-4383

Published: 2025

Journal Articles

Trends in acute TTP mortality amidst a shifting therapeutic landscape

Mathew Deucher, Madhumahita Maddukuri, Spero Cataland, Senthil Sukumar

Blood (2025) 146 (Supplement 1): 4885.

https://doi.org/10.1182/blood-2025-4885

Published: 2025

Journal Articles

High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS Consortium study

Sumithira Vasu, Qiuhong Zhao, Elizabeth Greer Miller, Patrick Elder, Lucille Langenberg, Spero Cataland, Stella M. Davies, Nelli Bejanyan, Theresa Hahn

Blood (2025) 146 (5): 638–646.

https://doi.org/10.1182/blood.2025028390

Published: 2025

Includes: Supplemental data

Journal Articles

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Hanny Al-Samkari, Vickie McDonald, Monica Carpenedo, Francesco Zaja, Nichola Cooper, Spero Cataland, Michael W Drazer, Yoshitaka Miyakawa, Marc Michel, Jaume Ayguasanosa, Janki Brahmbhatt, Lan Lan, Filip Matthijssens, Catherine M. Broome, Waleed Ghanima

Blood (2024) 144 (Supplement 1): 2570.1.

https://doi.org/10.1182/blood-2024-194816

Published: 2024

Journal Articles

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Blood (2024) 144 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2024-198872

Published: 2024

Journal Articles

More Than ADAMTS13: The Impact of Area Deprivation on Major Adverse Cardiovascular Events in Ittp Survivors

Senthil Sukumar, Jenna Brown, Marshall Mazepa, Spero Cataland, Shruti Chaturvedi

Blood (2024) 144 (Supplement 1): 140.

https://doi.org/10.1182/blood-2024-211400

Published: 2024

Journal Articles

Impaired Cognitive Function in Immune-TTP Is Better Predicted By Serum Thrombomodulin Than ADAMTS13 Activity: Results of a Longitudinal Multicenter Pilot Study

Aaron Boothby, Michael D Evans, Shangbin Yang, Senthil Sukumar, James G Scott, Deirdra Terrell, Spero Cataland, Marshall Mazepa

Blood (2023) 142 (Supplement 1): 1258.

https://doi.org/10.1182/blood-2023-181094

Published: 2023

Journal Articles

Thrombotic Thrombocytopenic Purpura (TTP) Survivors Exhibit Impaired Stress Perfusion on Cardiac MRI

Senthil Sukumar, Leah Danish, Ang Li, Yuchi Han, Spero Cataland

Blood (2023) 142 (Supplement 1): 696.

https://doi.org/10.1182/blood-2023-186331

Published: 2023

Journal Articles

Genetic Landscape of Thrombotic Microangiopathies with Focus on Plasminogen Mutation Variants

Shreya Agarwal, Senthil Sukumar, Camila Masias, Spero Cataland

Blood (2023) 142 (Supplement 1): 4002.

https://doi.org/10.1182/blood-2023-187248

Published: 2023

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

Fatigue and Cognition During Remission in Adults with Immune Thrombotic Thrombocytopenic Purpura

Shannon M Reeves, Amanda J Llaneza, Sara K. Vesely, Janna Journeycake, Mohamad O. Khawandanah, Marshall Mazepa, Frank Akwaa, Adam Cuker, Shruti Chaturvedi, Neil Zakai, Ming Yeong Lim, Radhika Gangaraju, San Keller, Spero Cataland, Deirdra R Terrell

Blood (2022) 140 (Supplement 1): 1228–1229.

https://doi.org/10.1182/blood-2022-170139

Published: 2022

Journal Articles

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Menapace, Ana Paula Marques, Sriya Gunawardena, Marie Scully

Blood (2022) 140 (Supplement 1): 5651–5653.

https://doi.org/10.1182/blood-2022-156306

Published: 2022

Journal Articles

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura

Hridaya Shah, Ann Kim, Senthil Sukumar, Marshall Mazepa, Ruhail Kohli, Evan M. Braunstein, Robert A. Brodsky, Spero Cataland, Shruti Chaturvedi

Blood (2022) 139 (16): 2570–2573.

https://doi.org/10.1182/blood.2022015545

Published: 2022

Includes: Supplemental data

Journal Articles

Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies

Bradley P. Dixon, Alvaro Domingo Madris-Aris, Brigitte Adams, David Kavanagh, Hee Gyung Kang, Jimmy Wang, Katherine Garlo, Kazuki Tanaka, Laurence Greenbaum, Masayo Ogawa, Nils Heyne, Seong Heon Kim, Spero Cataland, Sung-Soo Yoon, Yoshitaka Miyakawa, Yosu Luque, Melissa Muff-Luett

Blood (2021) 138 (Supplement 1): 769.

https://doi.org/10.1182/blood-2021-145040

Published: 2021

Journal Articles

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga Strebel, Jessica Minkue Mi Edou, Rui de Passos Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

Blood (2021) 138 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2021-148839

Published: 2021

Journal Articles

Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors

Deirdra Terrell, Rachel Ann Kelley, Amanda J Llaneza, Sara K. Vesely, Janna Journeycake, Mohamad O. Khawandanah, Marshall Mazepa, Frank Akwaa, Adam Cuker, Shruti Chaturvedi, Neil A. Zakai, Ming Yeong Lim, Radhika Gangaraju, Spero Cataland

Blood (2021) 138 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2021-153407

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial

A diagnostic hematology clinic pilot program: Increasing access and optimizing resources

Expert consensus on the clinical management of congenital thrombotic thrombocytopenic purpura in Asia-Pacific: A modified Delphi panel

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

Clinical management of congenital thrombotic thrombocytopenic purpura in Latin America: Expert consensus from a modified Delphi panel

Trends in acute TTP mortality amidst a shifting therapeutic landscape

High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS Consortium study

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

More Than ADAMTS13: The Impact of Area Deprivation on Major Adverse Cardiovascular Events in Ittp Survivors

Impaired Cognitive Function in Immune-TTP Is Better Predicted By Serum Thrombomodulin Than ADAMTS13 Activity: Results of a Longitudinal Multicenter Pilot Study

Thrombotic Thrombocytopenic Purpura (TTP) Survivors Exhibit Impaired Stress Perfusion on Cardiac MRI

Genetic Landscape of Thrombotic Microangiopathies with Focus on Plasminogen Mutation Variants

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Fatigue and Cognition During Remission in Adults with Immune Thrombotic Thrombocytopenic Purpura

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura

Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only